Allitinib
Alternative Names: Allitinib tosylate; ALS-1306; AST-1306Latest Information Update: 02 Oct 2021
At a glance
- Originator Allist Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 15 Mar 2016 No recent reports on development identified - Phase-I for Solid tumours (Late-stage disease) in China (PO)
- 30 May 2010 Phase-I trials in Solid tumours in China (PO)